Northwest Biotherapeutics (OTCMKTS:NWBO) Announces Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.02) earnings per share for the quarter, Zacks reports. The company had revenue of $0.23 million for the quarter.

Northwest Biotherapeutics Trading Down 7.0 %

Shares of Northwest Biotherapeutics stock traded down $0.02 during trading hours on Wednesday, reaching $0.21. The stock had a trading volume of 3,911,649 shares, compared to its average volume of 3,229,775. The firm has a market capitalization of $293.89 million, a PE ratio of -2.65 and a beta of -0.52. Northwest Biotherapeutics has a twelve month low of $0.20 and a twelve month high of $0.57. The stock’s 50 day moving average is $0.26 and its 200 day moving average is $0.28.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.